Phase 3 N=1,532 Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 88.5; 88.1 percentage of participants — p=0.98
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=57 Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
Prostate Cancer
Primary: Number of Participants With 5-year Freedom From Prostate Specific Antigen (PSA) Recurrence. — 30 participants
Phase 2 N=204 Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
Adenocarcinoma of the Prostate · Stage II Prostate Cancer
Primary: Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 3 (GG3) Biomarker Subgroups at…
Phase 3 N=2,028 Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Prostate Cancer
Primary: Overall Survival Rate (10-year) — 61.9; 56.8 percentage of patients — p=0.0309
Phase 2 N=16 Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 2; 6; 3 Participants
N/A N=101 A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer
Prostate Cancer
Primary: MP-erMRI Classification Sensitivity — 0.875 proportion of true positives
Phase 2 N=129 Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With Late Grade 3-5 Genitourinary (GU) and Gastrointestinal (GI) Adverse Events (AE) at 18 Months — 2.56 percentage of participants — p=<0.0001
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 2 N=20 PSMA Imaging of Localized Prostate Cancer
Prostate Cancer
Primary: The Number of Subjects With PSMA-positive (Prostate-specific Membrane Antigen) "Dominant" PC Lesion(s) Greater Than 5mm in Diameter, Whose Lesion(s) Have Been…
Phase 2 N=30 Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance
PSA Level Less Than or Equal to Fifteen · PSA Level Less Than Ten · Stage I Prostate Cancer AJCC v7
Primary: Change in Plasma IGF-1 From Baseline to Post-Treatment — 19.12; 8.54 ng/mL — p=0.190
Phase 2 N=32 Sequential Vaccinations in Prostate Cancer Patients
Prostatic Neoplasms
Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants
N/A N=25 MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer
MRI Guided Transurethral Ultrasound Ablation · Localized Prostate Cancer · Ablation Therapy
Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants
Phase 2 N=40 PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Prostate Neoplasms
Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…
N/A N=408 Prostate Cancer Screening Trial Using Imaging
Prostate Neoplasm
Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants
N/A N=5 Proton Radiotherapy for Stage I, IIA, and IIB Seminoma
Stage I, IIA and IIB Seminoma
Primary: Number of Serious Adverse Events — 0 Participants
Phase 3 N=731 Prostate Cancer Intervention Versus Observation Trial (PIVOT)
Prostate Cancer
Primary: All Cause Mortality — 171; 183 Participants
Phase 2 N=45 Radiation and Androgen Ablation for Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Biochemical Failure Free-rate (BFFR) Associated With the Combined Hypofractionated Dose Regimen and Androgen Deprivation Therapy (ADT). — 0 progression events
Phase 2 N=16 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) Response — 14 participants
Phase 2 N=5 Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer
Prostate Cancer
Primary: Treatment Tolerance (Genitourinary [GU] or Gastrointestinal [GI] Adverse Events) — 3 events
Phase 2 N=36 PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
Prostate Cancer
Primary: Diagnostic Accuracy of PSMA PET — 100; 74 percentage
Phase 2 N=35 Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
Phase 2 N=27 Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Dose Limiting Toxicities (Phase I and Safety Run-In) — 0; 0 Participants
N/A N=35 High-Dose Stereotactic Radiation for Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage I Prostate Cancer
Primary: Number of Patients With Treatment Related GI and/or GU Toxicity as Assessed by the NCI CTCTAE Version 4.0 — 1 Participants
Phase 2 N=42 Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer
Prostate Cancer
Primary: Change in the Number of Infiltrating CD3+ T Cells Within the Prostate Tissue Between the Biopsy and the Post-RP Tissue Specimens in Each Subject — 2.33; 2.03; 1.98; 6.39…
Phase 2 N=75 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Prostate Adenocarcinoma · Prostate Cancer · High Risk Prostate Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151
Phase 3 N=115 A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Negative Biopsies at Month 12 — 28; 17 Participants — p=0.0318
Phase 2 N=27 Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…
Phase 2 N=154 PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Stage I Prostate Adenocarcinoma AJCC v7 · Stage II Prostate Adenocarcinoma AJCC v7
Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2
N/A N=310 CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
Prostate Cancer · Prostatic Cancer · Prostate Neoplasms
Primary: Risk for Gastrointestinal (GI) and Genitourinary (GU) Toxicity — 0; 0; 0; 1.5 percentage of participants
Phase 2 N=80 Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…